The pharmacokinetics after intravenous and oral administration in man of the alpha 2-adrenoreceptor antagonist idazoxan (RX781094). 1986

N C Muir, and J G Lloyd-Jones, and J D Nichols, and J M Clifford

A high performance liquid chromatographic method was developed for the quantitative determination of idazoxan in plasma. The assay was used to study the disposition of the drug after intravenous infusion and oral administration to five normal subjects. After i.v. administration the kinetics could be described by a two compartment model with a mean elimination half life of 4.20 h. The mean calculated volume of distribution during the elimination phase was 3.20 l/kg-1 and the mean plasma clearance was 824 ml min-1. After oral administration a lag period before onset of absorption was observed in all five volunteers, the plasma levels declining monoexponentially from the peak concentration with a mean elimination half life of 5.58 h. The absolute availability varied between 26% and 41% with a mean value of 34%. In-vitro measurements produced a blood/plasma ratio of 1.3 for idazoxan.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D004146 Dioxanes Compounds that contain the structure 1,4-dioxane.
D004147 Dioxins A family of compounds that contain the 1,4-dioxin structure. Many specific dioxin derivatives are listed as CARCINOGENS; TERATOGENS; or MUTAGENS. Dioxin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000317 Adrenergic alpha-Antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. Adrenergic alpha-Receptor Blockaders,alpha-Adrenergic Blocking Agents,alpha-Adrenergic Receptor Blockaders,alpha-Blockers, Adrenergic,Adrenergic alpha-Blockers,alpha-Adrenergic Antagonists,alpha-Adrenergic Blockers,Adrenergic alpha Antagonists,Adrenergic alpha Blockers,Adrenergic alpha Receptor Blockaders,Agents, alpha-Adrenergic Blocking,Antagonists, alpha-Adrenergic,Blockaders, Adrenergic alpha-Receptor,Blockaders, alpha-Adrenergic Receptor,Blockers, alpha-Adrenergic,Blocking Agents, alpha-Adrenergic,Receptor Blockaders, alpha-Adrenergic,alpha Adrenergic Antagonists,alpha Adrenergic Blockers,alpha Adrenergic Blocking Agents,alpha Adrenergic Receptor Blockaders,alpha Blockers, Adrenergic,alpha-Antagonists, Adrenergic,alpha-Receptor Blockaders, Adrenergic
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D019329 Idazoxan A benzodioxane-linked imidazole that has alpha-2 adrenoceptor antagonist activity. Idazoxan Hydrochloride,RX-781094,Hydrochloride, Idazoxan,RX 781094,RX781094

Related Publications

N C Muir, and J G Lloyd-Jones, and J D Nichols, and J M Clifford
December 1983, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
N C Muir, and J G Lloyd-Jones, and J D Nichols, and J M Clifford
October 1999, Progress in neuro-psychopharmacology & biological psychiatry,
N C Muir, and J G Lloyd-Jones, and J D Nichols, and J M Clifford
September 1987, Journal of pharmacological methods,
N C Muir, and J G Lloyd-Jones, and J D Nichols, and J M Clifford
September 1979, European journal of clinical pharmacology,
N C Muir, and J G Lloyd-Jones, and J D Nichols, and J M Clifford
May 1999, The Journal of antimicrobial chemotherapy,
N C Muir, and J G Lloyd-Jones, and J D Nichols, and J M Clifford
July 1991, Arzneimittel-Forschung,
N C Muir, and J G Lloyd-Jones, and J D Nichols, and J M Clifford
October 1986, British journal of clinical pharmacology,
N C Muir, and J G Lloyd-Jones, and J D Nichols, and J M Clifford
September 1979, British journal of clinical pharmacology,
N C Muir, and J G Lloyd-Jones, and J D Nichols, and J M Clifford
January 1984, Postgraduate medical journal,
Copied contents to your clipboard!